STOCK TITAN

Stereotaxis to Report Second Quarter 2023 Financial Results on August 10, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Stereotaxis will release its financial results for the 2023 second quarter on August 10, 2023. The company will host a conference call and webcast to discuss the results and corporate developments.
Positive
  • Investors can gain insights into Stereotaxis' financial performance for the second quarter of 2023, which may positively impact the stock price.
Negative
  • None.

ST. LOUIS, July 17, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2023 second quarter on Thursday, August 10, 2023 before the open of the U.S. financial markets. The Company will host a conference call and webcast at 10 a.m. EST that day to discuss the Company’s results and corporate developments.

What:Stereotaxis second quarter 2023 financial results conference call
  
When:Thursday, August 10, 2023, at 10:00 a.m. ET (7:00 a.m. PT)
  
Dial In Number:To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 5648825.
  
Webcast:To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/.
  
Call Replay:A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here.

About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Investor Contacts:                                        
David L. Fischel                                        
Chairman and Chief Executive Officer                        
                                                        
Kimberly Peery                                                
Chief Financial Officer

314-678-6100
Investors@Stereotaxis.com

 


FAQ

When will Stereotaxis release its financial results for the 2023 second quarter?

Stereotaxis will release its financial results for the 2023 second quarter on August 10, 2023.

What will the conference call and webcast discuss?

The conference call and webcast will discuss Stereotaxis' financial results and corporate developments.

Where can I access the live and replay webcast?

You can access the live and replay webcast on the investor relations section of Stereotaxis' website at http://ir.stereotaxis.com/.

How long will the phone replay of the call be available?

The phone replay of the call will be available for one month beginning approximately four hours following the end of the call.

How can I request access for a replay of the conference call?

To request access for a replay of the conference call, please click on the provided link.

Stereotaxis, Inc.

NYSE:STXS

STXS Rankings

STXS Latest News

STXS Stock Data

172.47M
56.29M
15.87%
47.5%
1.13%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
ST.LOUIS

About STXS

stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. these innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. over 100 issued patents support the stereotaxis platform. the core components of stereotaxis’ systems have received regulatory clearance in the united states, european union, japan, canada, china, and elsewhere. for more information, please visit www.stereotaxis.com.